Publication | Closed Access

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

Overall SurvivalMedicineSecond Interim AnalysisMelanomaImmunologyPathologyImmune Checkpoint InhibitorCancer TreatmentFirst-line AtezolizumabOncologyRadiation OncologyMolecular Oncology